ReviewVirus genes2000
Marek's disease herpesvirus transforming protein MEQ: a c-Jun analogue with an alternative life style.
Review in Virus genes, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 66 citations in OpenAlex.
- Virulence of Marek's disease virus in Japan is linked to polymorphisms in theThe Journal of general virology · 2026Article
- Pathogenicity analysis and control strategies to combat avian diseases: mechanisms of increased virulence of Marek's disease virus and the development of vaccines against poultry red mites.The Journal of veterinary medical science · 2025Review
- Two distinct polymorphisms in the basic region of Meq protein of marek's disease virus alter pathological progression and clinical manifestations.Virology journal · 2025Article
- Amino acid insertion in the Meq protein of Marek's disease virus, an avian oncogenic herpesvirus, accelerates tumorigenesis.Microbiology spectrum · 2025Article
- Article
- Genomic characteristics and distinctive genetic polymorphisms of Marek's disease virus strains circulating in Japan.The Journal of veterinary medical science · 2025Article
- Programmed Cell Death-1 Expression in T-Cell Subsets in Chickens Infected with Marek's Disease Virus.Pathogens (Basel, Switzerland) · 2025Article
- Characterization of a Very Short Meq Protein Isoform in a Marek's Disease Virus Strain in Japan.Veterinary sciences · 2024Article
- Regulation of Wnt/β-catenin signaling by Marek's disease virusFrontiers in microbiology · 2024Article
- Article
- First report of Serotype-1 Marek's disease virus (MDV-1) with oncogenic form in backyard turkeys in Turkey: a molecular analysis study.BMC veterinary research · 2022Article
- Distinct polymorphisms in a single herpesvirus gene are capable of enhancing virulence and mediating vaccinal resistance.PLoS pathogens · 2020Article
- Genetic characterization of a Marek's disease virus strain isolated in Japan.Virology journal · 2020Article
- Marek's disease virus oncoprotein Meq physically interacts with the chicken infectious anemia virus-encoded apoptotic protein apoptin.Oncotarget · 2018Article
- First molecular detection and characterization of Marek's disease virus in red-crowned cranes (Grus japonensis): a case report.BMC veterinary research · 2018Article
- Isolation and purification of Gallid herpesvirus 2 strains currently distributed in Japan.The Journal of veterinary medical science · 2017Article
- Diversity of Meq gene from clinical Marek's disease virus infection in Saudi Arabia.Veterinary world · 2016Article
- Nuclear Factor kappa B is central to Marek's disease herpesvirus induced neoplastic transformation of CD30 expressing lymphocytes in-vivo.BMC systems biology · 2012Article
- Epigenetic regulation of the latency-associated region of Marek's disease virus in tumor-derived T-cell lines and primary lymphoma.Journal of virology · 2012Article
- Sequence analysis of the Meq gene in the predominant Marek's disease virus strains isolated in China during 2006-2008.Virus genes · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
In order to adapt to and to cope with an often hostile host environment, many viruses have evolved to encode products that are homologous to cellular proteins. These proteins exploit the existing host machinery and allow viruses to readily integrate into the host functional network. As a result, viruses are able to maneuver their journey seemingly effortlessly inside the host cell to achieve ultimate survival. Such molecular mimicries sometime go overboard, allowing viruses to overtake the cellular pathways or evade the immune system as do many of the retroviral oncogenes. Retroviral oncogenes are derived directly from host genes, and they are virtually identical to host genes in sequences except those mutations that make them unregulatable by host. Oncogenic herpesviruses also encode oncogenes, or transforming genes, which have independently evolved and are distantly related to host genes. However, these genes do share consensus structural motifs with cellular genes involved in cell growth and apoptosis and are functional analogues to host genes. The Marek's disease virus oncoprotein, MEQ, is one such example. MEQ is a basic region-leucine zipper (bZIP) transactivator which shares extensive homology with the Jun/Fos family of transcription factors within the bZIP domain, but not in other regions. Like all other bZIP proteins, MEQ is capable of dimerizing with itself and with a variety of bZIP partners including c-Jun, B-Jun, c-Fos, CREB, ATF-1, ATF-2, and SNF. MEQ-Jun heterodimers bind to a TRE/CRE-like sequence in the meq promoter region and have been shown to up-regulate MEQ expression in both chicken embryo fibroblasts and F9 cells. In addition, the bZIP and transactivation domains are interchangeable between MEQ and c-Jun in terms of transforming potential; i.e. MEQ can functionally substitute for c-Jun. These properties enable MEQ to engage in host cell processes by disguising itself as c-Jun. On the other hand, there are properties of MEQ notably different from c-Jun, which include its capability to bind RNA, to bind a CACAC-bent DNA structure as a homodimer, to inhibit apoptosis, and to interact with CDK2. MEQ's subcellular localization in the nucleolus and coiled body, is also different from Jun/Fos family of transactivators. These unique features may provide the MEQ with additional facility in regulating MDV replication, establishing latency, and cellular transformation. In this review, we will attempt to summarize the past research progress on MDV meq, with a focused on the similarities and differences between MEQ and cellular proteins, and between MEQ and other viral oncoproteins.
Indexed as
Identifiers
11022789W1562585824What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.